Katharina Möller, Madeleine Knöll, Elena Bady, Max Jonathan Schmerder, Sebastian Dwertmann Rico, Martina Kluth, Claudia Hube-Magg, Niclas C Blessin, Tim Mandelkow, Maximilian Lennartz, Anne Menz, Andreas M Luebke, Doris Höflmayer, Christoph Fraune, Christian Bernreuther, Patrick Lebok, Ria Uhlig, Hendrina Contreras, Sören Weidemann, Natalia Gorbokon, Frank Jacobsen, Till S Clauditz, Stefan Steurer, Eike Burandt, Sarah Minner, Guido Sauter, Ronald Simon, Andreas H Marx, Till Krech
BACKGROUND: Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking. MATERIALS AND METHODS: We analyzed immunohistochemical PD-L1 expression in 11,838 samples from 118 human tumor types and its relationship with tumor infiltrating CD8 positive lymphocytes. RESULTS: At a cut-off level of 10% positive tumor cells, PD-L1 positivity was seen in 85 of 118 (72%) tumor types, including thymoma (100% positive), Hodgkin's lymphoma (93%), anaplastic thyroid carcinoma (76%), Kaposi sarcoma (71%), sarcomatoid urothelial carcinoma (71%), and squamous cell carcinoma of the penis (67%), cervix (65%), floor of the mouth (61%), the lung (53%), and pharynx (50%)...
January 11, 2023: Cancer Biomarkers: Section A of Disease Markers